195
Views
0
CrossRef citations to date
0
Altmetric
Review

Palliative treatment of malignant ascites: profile of catumaxomab

&
Pages 103-110 | Published online: 14 May 2010

References

  • ChungMKozuchPTreatment of malignant ascitesCurr Treat Options Oncol20089221523318777213
  • FlemingNDAlvarez-SecordAVon GruenigenVMillerMJAbernethyAPIndwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart reviewJ Pain Symptom Manage200938334134919328648
  • BeckerGMedical and palliative management of malignant ascitesCancer Treat Res200713445946717633074
  • ShenJZhuZCatumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancerCurr Opin Mol Ther200810327328418535935
  • AyantundeAAParsonsSLPattern and prognostic factors in patients with malignant ascites: a retrospective studyAnn Oncol200718594594917298959
  • GarrisonRNGallowayRHHeuserLSMechanisms of malignant ascites productionJ Surg Res19874221262434730
  • ZebrowskiBKLiuWRamirezKMarkedly elevated levels of vascular endothelial growth factor in malignant ascitesAnn Surg Oncol19996437337810379858
  • FanLYIsekiSImmunohistochemical localization of vascular endothelial growth factor in the globule leukocyte/mucosal mast cell of the rat respiratory and digestive tractsHistochem Cell Biol1999111113219930879
  • KraftAWeindelKOchsAVascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseaseCancer19998511781879921991
  • GarrisonRNKaelinLDGallowayRHHeuserLSMalignant ascites. Clinical and experimental observationsAnn Surg198620366443718029
  • MasabumiSMasashiTSachikoYInvolvement of VEGF and its receptors in ascites tumor formationCancer Chemother Pharmacol1999430S72S7710357563
  • LissoniPRovelliFMaluganiFChanges in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancerThe Int J Biol Markers2003182152155
  • ParsonsSLWatsonSASteeleRJCMalignant ascitesBr J Surg19968316148653366
  • BeattieGJSmythJFPhase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascitesClin Cancer Res199848189919029717817
  • FerrellBSmithSLCullinaneCAMelanconCPsychological well being and quality of life in ovarian cancer survivorsCancer20039851061107112942576
  • CattauELJrBenjaminSBKnuffTECastellDOThe accuracy of the physical examination in the diagnosis of suspected ascitesJAMA1982247811647057606
  • InadomiJCelloJPKochJUltrasonographic determination of ascitic volumeHepatology19962435495518781322
  • WalkeyMMFriedmanACSohotraPRadeckiPDCT manifestations of peritoneal carcinomatosisAm J Roentgenol19881505103510413258703
  • AkriviadisEAHemoperitoneum in patients with ascitesAm J Gastroenterol19979245679128301
  • PressOWPressNOKaufmanSDEvaluation and management of chylous ascitesAnn Intern Med19829633587059101
  • RunyonBAMontanoAAAkriviadisEAThe serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascitesAnn Intern Med199211732151616215
  • CardozoPLA critical evaluation of 3,000 cytologic analyses of pleural fluid, ascitic fluid and pericardial fluidActa Cytol196610455460
  • LoewensteinMSRittgersRAFeinermanAECarcinoembryonic antigen assay of ascites and detection of malignancyAnn Intern Med1978885635646247
  • ParsonsSLLangMWSteeleRJCMalignant ascites: a 2-year review from a teaching hospitalEur J Surg Oncol19962232372398654603
  • MackeyJRVennerPMMalignant ascites: demographics, therapeutic efficacy and predictors of survivalCan J Oncol19966247448012056099
  • BeckerGGalandiDBlumHEMalignant ascites: systematic review and guideline for treatmentEur J Cancer200642558959716434188
  • McNamaraPParacentesis – an effective method of symptom control in the palliative care setting?Palliat Med2000141626410717726
  • StephensonJGilbertJThe development of clinical guidelines on paracentesis for ascites related to malignancyPalliat Med200216321312046997
  • RunyonBAManagement of adult patients with ascites caused by cirrhosisHepatology19982712642729425946
  • SalernoFBadalamentiSIncertiPRepeated paracentesis and iv albumin infusion to treat ‘tense’ ascites in cirrhotic patients: a safe alternative therapyJ Hepatol1987511023655306
  • GinesPTitoELArroyoVRandomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosisGastroenterology198894614933360270
  • GotliebWHFeldmanBFeldman-MoranOIntraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancerGynecol Oncol19987133813859887235
  • LeeCWBociekGFaughtWA survey of practice in management of malignant ascitesJ Pain Symptom Manage1998162961019737100
  • PockrosPJEsrasonKTNguyenCDuqueJWoodsSMobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristicsGastroenterology19921034130213061397889
  • GreenwayBJohnsonPJWilliamsRControl of malignant ascites with spironolactoneBr J Surg19826984414427049306
  • SharmaSWalshDManagement of symptomatic malignant ascites with diuretics: two case reports and a review of the literatureJ Pain Symptom Manage19951032372427629417
  • GoughIRBaldersonGAMalignant ascites. A comparison of peritoneovenous shunting and nonoperative managementCA Cancer J Clin199371723772382
  • LeVeenHHWapnickSGrosbergSKinneyMJFurther experience with peritoneo-venous shunt for ascitesAnnals Surg19761845574
  • QaziRSavlovEDPeritoneovenous shunt for palliation of malignant ascitesCA Cancer J Clin1982493600602
  • EdneyJAHillAArmstrongDPeritoneovenous shunts palliate malignant ascitesAm J Surg198915865982480068
  • SmithDAWeaverDWBouwmanDLPeritoneovenous shunt (PVS) for malignant ascites: an analysis of outcomeAm Surgeon19895574452742227
  • CheungDKRaafJHSelection of patients with malignant ascites for a peritoneovenous shuntCA Cancer J Clin198250612041209
  • SmithEMJaysonGCThe current and future management of malignant ascitesClin Oncol (R Coll Radiol)2003152597212708713
  • AdamRAAdamYGMalignant ascites: past, present, and futureJ Am Coll Surg20041986999101115194082
  • OzkanOAkinciDGocmenRCilBOzmenMAkhanOPercutaneous placement of peritoneal port-catheter in patients with malignant ascitesCardiovasc Intervent Radiol200730223223617206391
  • BrooksRAHerzogTJLong-term semi-permanent catheter use for the palliation of malignant ascitesGynecol Oncol2006101236036216499957
  • RosenbergSMPalliation of malignant ascitesGastroenterol Clin N2006351189199
  • CairnsWMaloneROctreotide as an agent for the relief of malignant ascites in palliative care patientsPalliat Med199913542943010659116
  • HuangSRobinsonJBDeguzmanABucanaCDFidlerIJBlockade of nuclear factor κ-B signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8Cancer Res20006019533411034066
  • XuLYonedaJHerreraCWoodJKillionJJFidlerIJInhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinasesInt J Oncol200016344545410675474
  • BeattieGJSmythJFPhase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascitesClin Cancer Res199848189919029717817
  • StuartGCENationJGSniderDDThunbergPIntraperitoneal interferon in the management of malignant ascitesCA Cancer J Clin199371620272030
  • EinhornNLingPEinhornSStranderHA phase II study on escalating interferon doses in advanced ovarian carcinomaAm J Clin Oncol198811133277373
  • RathUKaufmannMSchmidHEffect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascitesEur J Cancer19912721211827272
  • SebastianMKiewePSchuetteWTreatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 studyJ Immunother200932219520219238019
  • Revill MelyNBozzoJCatumaxomab Anti-Ep-CAM Monoclonal AntibodyDrugs Future2008335385391
  • ZeidlerRReisbachGWollenbergBSimultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killingJ Immunol19991633124610415020
  • ZeidlerRMysliwietzJCsanadyMThe Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cellsBr J Cancer200083226126610901380
  • StanojeviZRaniGRadiSPathogenesis of malignant ascites in ovarian cancer patientsArchive of Oncology2004122115118
  • BurgesAWimbergerPKumperCEffective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyClin Cancer Res200713133899390517606723